Anti-B7H7 Monoclonal Antibody HBM1020

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A recombinant human monoclonal antibody directed against HERV-H LTR-associating protein 2 (HHLA2; B7 homolog 7; B7H7), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-B7H7 monoclonal antibody HBM1020 binds to B7H7 and blocks the interaction between B7H7 and its receptors. This abrogates the B7H7-mediated inhibition of T-cell and nature killer (NK) cell activation, which may lead to enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response and NK cell cytotoxicity against cancer cells. B7H7, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and a negative regulator of T-cell and NK cell activation.

**Synonyms:** - Anti-HHLA2 Monoclonal Antibody HBM1020 - HBM 1020 - HBM-1020 - HBM1020